Approval · Notice of Compliance 10295 · 2009
ACCEL-RANITIDINE: Notice of Compliance 10295
Issued June 24, 2009
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 10295
- Date
- June 24, 2009
- Company
- Accel Pharma IncPointe Claire, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Abbreviated New Drug Submission (ANDS)
- Submission class
- Other
- Therapeutic class
- Histamine H2-receptor antagonist
- Canadian reference product
- ZANTAC (Glaxosmithkline Inc)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| ACCEL-RANITIDINE | 02327244 | — |
| ACCEL-RANITIDINE | 02327252 | — |
Medicinal ingredients
- RANITIDINE HCL 150 MG per TAB
- RANITIDINE HCL 300 MG per TAB